Redeye presents its preview for Senzime’s Q3 2025 report, due on October 29.
Redeye comments on Fractal’s Q3 report, which highlighted strong end-customer demand but soft headli...
Redeye comments on Avensia’s Q3 report showing a softer EBIT than expected, as lower sales are facin...
Vaisala’s Q3 results beat estimates due to W&E projects.
SRV’s Q3 profitability reflected current lower volumes and lack of revenue from other than contracti...
We open up for questions on our Q3 update.
* Sales in-line with CTT's guidance, EBIT below ABGSCe * Removed Q4 guidance due to increased short-...
* Sales +1% and adj. EBITA +29% vs ABGSCe * Strong within defence and cybersecurity * Consensus EBIT...
* Q3 sales 3% below our ests. at SEK 214m, for 9.4% org.
Redeye comments on CombinedX’s Q3 report showing roughly flat organic growth and a solid rebound in ...
Redeye provides an initial comment on Safeture’s Q3 2025 report, where the company delivered a seque...
Redeye comments on Addnode’s Q3 report showing solid margins in PLM and PM.
Redeye comments on Sleep Cycle’s Q3 report, which was in line with expectations.
Redeye updates its view on Nanologica following what we view as an undramatic Q3 2025 report.
Redeye provides its initial take on Lifco’s Q3 2025 report, which aligned with our estimates.
